This is a working overview of synthetic peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-29 and is reviewed periodically as new material appears.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
=== True protein === In at least one segment of the food industry, the dairy industry, some countries (at least the U.S., Australia, France and Hungary) have adopted "true protein" measurement, as opposed to crude protein measurement, as the standard for payment and testing: "True protein is a measure of only the proteins in milk, whereas crude protein is a measure of all sources of nitrogen and includes nonprotein nitrogen, such as urea, which has no food value to humans. ... Current milk-testing equipment measures peptide bonds, a direct measure of true protein." Measuring peptide bonds in grains has also been put into practice in several countries including Canada, the UK, Australia, Russia and Argentina where near-infrared reflectance (NIR) technology, a type of infrared spectroscopy is used. The more traditional approach to true protein analysis is amino acid analysis. Data from such analysis has additional nutritional meaning, as humans and other animals have specific requirements for essential amino acids. The Food and Agriculture Organization of the United Nations (FAO) recommends that only amino acid analysis be used to determine protein in, inter alia, foods used as the sole source of nourishment, such as infant formula, but also provides: "When data on amino acids analyses are not available, determination of protein based on total N content by Kjeldahl (AOAC, 2000) or similar method ...
{\displaystyle {\begin{aligned}[][a_{0},a_{1},a_{2},a_{3}]&=[0.616634218997,0.108855827811,0.023453835635,0.000449332509]\\[][b_{1},b_{2},b_{3},b_{4},b_{5},b_{6}]&=[1.919948267476,1.635304362591,0.799392556572,0.240278859212,0.043178653945,0.003863334276]\end{aligned}}}
== Tritium breeding == Fusion reactions, such as those in the proposed ITER thermonuclear demonstrator reactor, are fueled by tritium and deuterium. Tritium resources are extremely limited in their availability, with total resources currently estimated at twenty kilograms. Lithium-containing ceramic pebbles can be used as solid breeder materials in a component known as a helium-cooled breeder blanket for the production of tritium. The breeding blanket constitutes a key component of the ITER reactor design. In such reactor designs tritium is produced by neutrons leaving the plasma and interacting with lithium in the blanket. Li2TiO3 along with Li4SiO4 are attractive as tritium breeding materials because they exhibit high tritium release, low activation, and chemical stability.
== Selected publications == Moloney, P. J. (1926). "The preparation and testing of diphtheria toxoid (Anatoxine-Ramon)". American Journal of Public Health. 16 (12): 1208–1210. doi:10.2105/AJPH.16.12.1208. PMC 1321494. PMID 18012024. Moloney, P. J.; Fraser, C. J. (1927). "Immunization with diphtheria toxoid (anatoxine Ramon)". American Journal of Public Health. 17 (10): 1027–1030. doi:10.2105/AJPH.17.10.1027. PMC 1321911. PMID 18012293. Taylor, E. M.; Moloney, P. J. (1939). "A New Schick-Toxin". The Journal of Immunology. 37 (3): 223–232. doi:10.4049/jimmunol.37.3.223. S2CID 86572393. Fitzgerald, J. G.; Defries, R. D.; Fraser, D. T.; Moloney, P. J.; McKinnon, N. E. (1932). "Experiences with Diphtheria Toxoid in Canada". American Journal of Public Health and the Nation's Health. 22 (1): 25–28. doi:10.2105/ajph.22.1.25. PMC 1556712. PMID 18013424. Moloney, P. J.; Hennessy, J. N. (1942). "Purification of tetanus toxoid". The Biochemical Journal. 36 (7–9): 544–547. doi:10.1042/bj0360544. PMC 1266838. PMID 16747558. Moloney, P. J.; Hennessy, Joan N. (1944). "Titration of Tetanal Toxins and Toxoids by Flocculation". The Journal of Immunology. 48 (6): 345–354. doi:10.4049/jimmunol.48.6.345. S2CID 88201977. Moloney, P. J.; Coval, M. (1955). "Antigenicity of insulin: Diabetes induced by specific antibodies". The Biochemical Journal. 59 (2): 179–185. doi:10.1042/bj0590179. PMC 1216116. PMID 14351177. Moloney, P. J.; Goldsmith, L. (1957). "On the Antigenicity of Insulin". Canadian Journal of Biochemistry and Physiology. 35 (1): 79–92. doi:10.1139/y57-011. PMID 13396665.
Sources: en.wikipedia.org
However, insulin therapy may be conducted without CGM and although there is not yet an automated insulin-regulation feedback mechanism between measure and infusion to control the amount and timing of insulin, this is clearly a future objective. Any change in basal or bolus is patient-driven by programming the pump using the Bolus Wizard. The latest model pumps are the MiniMed Paradigm 522 and 722, which differ in reservoir size, 176 versus 300 units, respectively. In 2007 the FDA approved a pediatric model for patients 7 to 17 years old.
== Career and research == He moved to the Department of Pharmaceutical Chemistry the University of California, San Francisco in the early 1970s. He founded the Molecular Design Institute at UCSF in 1993. He was awarded the UCSF medal in 2018.
Smooth muscle is involuntary and non-striated. It is divided into two subgroups: the single-unit (unitary) and multiunit smooth muscle. Within single-unit cells, the whole bundle or sheet contracts as a syncytium (i.e. a multinucleate mass of cytoplasm that is not separated into cells). Multiunit smooth muscle tissues innervate individual cells; as such, they allow for fine control and gradual responses, much like motor unit recruitment in skeletal muscle. Smooth muscle is found within the walls of blood vessels (such smooth muscle specifically being termed vascular smooth muscle) such as in the tunica media layer of the large (aorta) and small arteries, arterioles and veins. Smooth muscle is also found in lymphatic vessels, the urinary bladder, uterus (termed uterine smooth muscle), male and female reproductive tracts, the gastrointestinal tract, the respiratory tract, the arrector pili of skin, the ciliary muscle, and the iris of the eye. The structure and function is basically the same in smooth muscle cells in different organs, but the inducing stimuli differ substantially, in order to perform individual actions in the body at individual times. In addition, the glomeruli of the kidneys contain smooth muscle-like cells called mesangial cells.
Zearalenone (ZEN), also known as RAL and F-2 mycotoxin, is a potent estrogenic metabolite produced by some Fusarium and Gibberella species. Specifically, the Gibberella zeae, the fungal species where zearalenone was initially detected, in its asexual/anamorph stage is known as Fusarium graminearum. Several Fusarium species produce toxic substances of considerable concern to livestock and poultry producers, namely deoxynivalenol, T-2 toxin, HT-2 toxin, diacetoxyscirpenol (DAS) and zearalenone. Particularly, ZEN is produced by Fusarium graminearum, Fusarium culmorum, Fusarium cerealis, Fusarium equiseti, Fusarium verticillioides, and Fusarium incarnatum. Zearalenone is the primary toxin that binds to estrogen receptors, causing infertility, abortion or other breeding problems, especially in swine. Often, ZEN is detected together with deoxynivalenol in contaminated samples and its toxicity needs to be considered in combination with the presence of other toxins. Zearalenone is heat-stable and is found worldwide in a number of cereal crops, such as maize, barley, oats, wheat, rice, and sorghum. Its production increases when the climate is warm with air humidity at or above twenty percent. The environmental pH plays also a role in the toxin's production. When temperatures fall to 15 °C, alkaline soils still support ZEN production. At the preferred Fusarium temperature, which ranges between 25 °C and 30 °C, neutral pH results in the greatest toxin production.
2 March Chinese People's Liberation Army troops attacked Soviet border guards on Zhenbao Island, marking a new low in relations between North Vietnam's principal allies. Village and hamlet elections were held throughout South Vietnam, largely free of PAVN/VC interference.
Sources: en.wikipedia.org
== Development and test sites == Stephanie Fitzpatrick, an American geopolitical consultant, has claimed that the Chemical Research Institute in Nukus, Soviet Uzbekistan, produced Novichok agents, and The New York Times has reported that U.S. officials said the site was the major research and testing site for Novichok agents. Small, experimental batches of the weapons may have been tested on the nearby Ustyurt Plateau. Fitzpatrick also writes that the agents may have been tested in a research centre in Krasnoarmeysk near Moscow. Precursor chemicals were made at the Pavlodar Chemical Plant in Soviet Kazakhstan, which was also thought to be the intended Novichok weapons production site, until its still-under-construction chemical warfare agent production building was demolished in 1987 in view of the forthcoming 1990 Chemical Weapons Accord and the Chemical Weapons Convention. Since its independence in 1991, Uzbekistan has been working with the government of the United States to dismantle and decontaminate the sites where the Novichok agents and other chemical weapons were tested and developed. Between 1999 and 2002 the United States Department of Defense dismantled the major research and testing site for Novichok at the Chemical Research Institute in Nukus, under a $6 million Cooperative Threat Reduction program.
Chinese officials described these criticisms as an attempt to politicise the study. Scientists involved in the WHO report, including Liang Wannian, John Watson, and Peter Daszak, objected to the criticism, and said that the report was an example of the collaboration and dialogue required to successfully continue investigations into the matter. In a letter published in Science, a number of scientists, including Ralph Baric, argued that the accidental laboratory leak hypothesis had not been sufficiently investigated and remained possible, calling for greater clarity and additional data. Their letter was criticized by some virologists and public health experts, who said that a "hostile" and "divisive" focus on the WIV was unsupported by evidence, and would cause Chinese scientists and authorities to share less, rather than more data.
66th Academy Awards (1994): Best Supporting Actor, nomination, for What's Eating Gilbert Grape 77th Academy Awards (2005): Best Actor, nomination, for The Aviator 79th Academy Awards (2007): Best Actor, nomination, for Blood Diamond 86th Academy Awards (2014): Best Picture and Best Actor, nominations, for The Wolf of Wall Street 88th Academy Awards (2016): Best Actor, win, for The Revenant 92nd Academy Awards (2020): Best Actor, nomination, for Once Upon a Time in Hollywood 98th Academy Awards (2026): Best Actor, nomination, for One Battle After Another DiCaprio has won three Golden Globe Awards: Best Actor – Motion Picture Drama for The Aviator and The Revenant and Best Actor – Motion Picture Musical or Comedy for The Wolf of Wall Street, as well as a BAFTA Award and a Screen Actors Guild Award for Best Actor for The Revenant.
Release of the transverse carpal ligament is undertaken in carpal tunnel surgery. The purpose of cutting the transverse carpal ligament is to relieve pressure on the median nerve, and this is a type of nerve decompression surgery. It is recommended when there is constant (not just intermittent) numbness, muscle weakness, or atrophy, and when night-splinting or other palliative interventions no longer alleviate intermittent symptoms. The surgery may be done with local or regional anesthesia with or without sedation, or under general anesthesia. In general, milder cases can be controlled without surgery for months to years, but severe cases are unrelenting symptomatically and are likely to result in surgical treatment.
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.
Prothymosin alpha is a much larger acidic protein, roughly 111 to 113 residues long, and the thymosin alpha-1 sequence matches its N-terminal region. The small peptide is therefore best understood as a fragment of that parent protein rather than a separate gene product.
Trials and clinical reports have examined chronic hepatitis B and C, use as a vaccine adjuvant, and supportive treatment in some immunodeficiency and oncology settings. Results vary by indication, and regulatory approval differs between countries.